LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Variant classification summary
NM_004119.2:c.1664T>A
FLT3
· NP_004110.2:p.(Ile555Asn)
· NM_004119.2
GRCh37: chr13:28608478 A>T
·
GRCh38: chr13:28034341 A>T
Gene:
FLT3
Transcript:
NM_004119.2
Final call
VUS
PM2 moderate
Variant details
Gene
FLT3
Transcript
NM_004119.2
Protein
NP_004110.2:p.(Ile555Asn)
gnomAD AF
1.2390591080756917e-06 (v4.1)
ClinVar
OncoKB
Unknown Oncogenic Effect
Classification rationale
Interpretation summary
Generated evidence synthesis
1
PM2 Moderate: gnomAD v4.1 frequency is 1.23906e-06 with zero homozygotes.
2
VUS: PM2 Moderate alone satisfies no pathogenic or benign combination rule.
Final determination:
Under the local FLT3 framework's ACMG/AMP combination rules, one Moderate criterion alone does not meet any Pathogenic, Likely Pathogenic, Benign, or Likely Benign rule; therefore the call is VUS.
Criteria assessment
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
| Criterion | Status | Rationale | Evidence used |
|---|---|---|---|
| PVS1 | N/A | Not applicable: c.1664T>A is a missense substitution, not one of the null-variant classes required for PVS1. |
pvs1_variant_assessment
|
| PS1 | Not met | Not met: no previously established pathogenic variant producing FLT3 p.Ile555Asn was identified for this missense substitution. |
|
| PS2 | Not assessed | Not assessed: no proband-level de novo evidence or confirmed maternity and paternity testing is available for p.Ile555Asn. |
|
| PS3 | Not assessed | Not assessed: no variant-specific functional assay was identified, and OncoKB reports Unknown Oncogenic Effect rather than exact-variant functional evidence. |
oncokb
PMID:40637740
vcep_flt3_itd_hotspot_and_function
vcep_flt3_oncokb_guidance
|
| PS4 | Not met | Not met: no variant-specific affected-versus-control carrier counts, odds ratio, or confidence interval were reported for p.Ile555Asn. |
PMID:40637740
|
| PM1 | Not met | Not met: FLT3 residue 555 is outside the governing codons 589-599 hotspot, and vcep_materials.json lists no approved critical-domain entry for residue 555. |
vcep_flt3_itd_hotspot_and_function
hotspots
|
| PM2 | Met | Met at Moderate: gnomAD v4.1 total AF is 1.23906e-06 with 0 homozygotes, below the <=0.0001 PM2 cutoff. |
gnomad_v2
gnomad_v4
|
| PM3 | N/A | Not applicable: PM3 is restricted to recessive disorders, but no recessive FLT3 disorder or in-trans pathogenic allele is established. |
|
| PM4 | N/A | Not applicable: p.Ile555Asn changes one amino acid but causes no protein-length change required for PM4. |
pvs1_variant_assessment
vcep_flt3_itd_hotspot_and_function
|
| PM5 | Not met | Not met: no different pathogenic missense variant at FLT3 residue 555 was identified, and the local PM5 note excludes this missense SNV. |
vcep_flt3_itd_hotspot_and_function
vcep_flt3_oncokb_guidance
pm5_candidates
|
| PM6 | Not assessed | Not assessed: no assumed de novo occurrence or parental testing data are reported for p.Ile555Asn. |
|
| PP1 | Not assessed | Not assessed: zero affected relatives and zero informative co-segregating meioses are documented for p.Ile555Asn. |
|
| PP2 | Not assessed | Not assessed: the required FLT3 benign-missense rate and evidence that missense variants commonly cause disease are not provided. |
|
| PP3 | Not met | Not met: missense REVEL score 0.561 is below the PP3 supporting threshold of >= 0.644. |
revel
|
| PP4 | Not assessed | Not assessed: no patient phenotype, family history, or disease diagnosis is available to evaluate phenotype specificity. |
|
| PP5 | Not met | Not met: the exact variant has no ClinVar expert-panel pathogenic or likely pathogenic classification. |
|
| BA1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 3.65e-06 (0.000365%), far below the >=0.05 BA1 threshold. |
gnomad_v4
|
| BS1 | Not met | Not met: gnomAD v4.1 grpmax FAF is 3.65e-06 (0.000365%), below the generic 0.01 BS1 threshold. |
gnomad_v4
|
| BS2 | Not assessed | Not assessed: gnomAD has 0 homozygotes, but disease model, penetrance, and healthy-adult status for the rare heterozygotes are unavailable. |
gnomad_v2
gnomad_v4
|
| BS3 | Not assessed | Not assessed: no variant-specific assay demonstrated a lack of damaging effect on FLT3 protein function or splicing. |
oncokb
PMID:40637740
vcep_flt3_itd_hotspot_and_function
vcep_flt3_oncokb_guidance
|
| BS4 | Not assessed | Not assessed: no affected relatives have documented negative testing, so no non-segregation event is available for BS4. |
|
| BP1 | Not assessed | Not assessed: no validated evidence shows that FLT3 disease is caused primarily by truncating variants. |
|
| BP2 | Not assessed | Not assessed: no reported pathogenic partner variant or parental phase result establishes cis or trans occurrence for p.Ile555Asn. |
|
| BP3 | N/A | Not applicable: p.Ile555Asn is a missense SNV, not an in-frame deletion or insertion in a repetitive region. |
pvs1_variant_assessment
vcep_flt3_itd_hotspot_and_function
|
| BP4 | Not met | Not met: missense REVEL score 0.561 is above the BP4 supporting threshold of <= 0.29. |
revel
|
| BP5 | Not assessed | Not assessed: no case-level alternate molecular basis for disease is documented alongside this variant. |
|
| BP6 | Not met | Not met: the exact variant has no ClinVar expert-panel benign or likely benign classification. |
|
| BP7 | N/A | Not applicable: c.1664T>A is missense with p.(Ile555Asn), not a synonymous variant. |
|
Disclaimer:
The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.